Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors

Blood Advances

Volumn 1, Issue 22, 2017, Pages 1891-1899

  Shima, Midori ^a   Hanabusa, Hideji ^b   Taki, Masashi ^c   Matsushita, Tadashi ^d   Sato, Tetsuji ^e   Fukutake, Katsuyuki ^f   Kasai, Ryu ^g   Yoneyama, Koichiro ^g   Yoshida, Hiroki ^g   Nogami, Keiji ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b Ogikubo Hospital   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NAGOYA UNIVERSITY   (Japan)

^e UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^f TOKYO MEDICAL UNIVERSITY   (Japan)

^g CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85041670842     PISSN: 24739529     EISSN: 24739537     Source Type: Journal    
DOI: 10.1182/bloodadvances.2017006684     Document Type: Article

References (28)

1. Mannucci PM, Tuddenham EG. The hemophilias-from royal genes to gene therapy. N Engl J Med. 2001; 344(23):1773-1779.
2. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003; 361(9371):1801-1809.
3. Tsailas PG, Wiedel JD. Arthrodesis of the ankle and subtalar joints in patients with haemophilic arthropathy. Haemophilia. 2010; 16(5):822-831.
4. Ferreira AA, Leite IC, Bustamante-Teixeira MT, et al. Health-related quality of life in hemophilia: Results of the Hemophilia-Specific Quality of Life Index (Haem-a-Qol) at a Brazilian blood center. Rev Bras Hematol Hemoter. 2013; 35(5):314-318.
5. Luck JV Jr, Silva M, Rodriguez-Merchan EC, Ghalambor N, Zahiri CA, Finn RS. Hemophilic arthropathy. J Am Acad Orthop Surg. 2004; 12(4): 234-245.
6. Coppola A, Di Capua M, Di Minno MN, et al. Treatment of hemophilia: A review of current advances and ongoing issues. J Blood Med. 2010; 1:183-195.
7. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment Guidelines Working Group on Behalf of the World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013; 19(1):e1-e47.
8. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007; 357(6):535-544.
9. Shire plc. ADVATE (antihemophilic factor [recombinant]): Prescribing information (November 2016). http://www.shirecontent.com/PI/PDFs/ADVATE_USA_ENG.pdf. Accessed 30 May 2017.
10. Bayer HealthCare LLC. KOGENATE FS (antihemophilic factor [recombinant], formulated with sucrose): Prescribing information (May 2016). http://labeling.bayerhealthcare.com/html/products/pi/Kogenate_BIO-SET_PI.pdf. Accessed 30 May 2017.
11. Pfizer Inc. ReFacto (antihemophilic factor [recombinant]): Prescribing information (December 2007). http://labeling.pfizer.com/showlabeling.aspx? id5140. Accessed 30 May 2017.
12. Biogen Inc. ELOCTATE (antihemophilic factor [recombinant], Fc fusion protein): Prescribing information (January 2017). https://www.eloctate.com/Pdfs/full-prescribing-information.pdf. Accessed 30 May 2017.
13. Shire plc. ADYNOVATE (antihemophilic factor [recombinant], PEGylated): Prescribing information (March 2017). http://www.shirecontent.com/PI/PDFs/ADYNOVATE_USA_ENG.pdf. Accessed 30 May 2017.
14. Powell JS. Recombinant factor VIII in the management of hemophilia A: Current use and future promise. Ther Clin Risk Manag. 2009; 5(2):391-402.
15. Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia. 2014; 20(suppl 4):99-105.
16. Witmer C, Young G. Factor VIII inhibitors in hemophilia A: Rationale and latest evidence. Ther Adv Hematol. 2013; 4(1):59-72.
17. Tagariello G, Iorio A, Matino D, et al. High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance. J Hematol Oncol. 2013; 6:63.
18. Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012; 18(10):1570-1574.
19. Sampei Z, Igawa T, Soeda T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One. 2013; 8(2):e57479.
20. Muto A, Yoshihashi K, Takeda M, et al. Anti-factor IXa/X bispecific antibody (ACE910): Hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014; 12(2):206-213.
21. Muto A, Yoshihashi K, Takeda M, et al. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood. 2014; 124(20):3165-3171.
22. Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016; 127(13):1633-1641.
23. Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016; 374(21): 2044-2053.
24. Mikaelsson M, Oswaldsson U. Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products. Semin Thromb Hemost. 2002; 28(3):257-264.
25. Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet. 2013; 52(2):83-124.
26. Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017; 117(7):1348-1357.
27. Adamkewicz J, Muto A, Soeda T, Suzuki S, Kitazawa T. In vitro thrombin generation testing and in vivo venous stasis model for assessing the procoagulant effects of FVIII, emicizumab, rFVIIa, and aPCC [abstract]. Haemophilia. 2017; 23(suppl 2):26. Abstract OR37.
28. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017; 377(9):809-818.